Form D · Biotechnology
Eye Care International LLC
Cambridge, MA · CIK 0001969977
Offering snapshot reported May 20, 2024 · SEC filing
- Reported sold
- $710K Offering amount: $2.5M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- May 2, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 20, 2024 | Initial | $710,000 | No comparison | 8 | SEC filing |
| Mar 17, 2023 | Initial | $1,400,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-513695
Convertible Promissory Note
Source: Form D, filed May 20, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ronald Gentile | Director, Executive |
| Lloyd Hildebrand | Director |
| Evan Myrianthropolous | Director |
| Elan Weiner | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
700 Main Street
Cambridge, MA, 02139
Cambridge, MA, 02139